Glaxosmithkline Biologicals Sa

Janssen Pharmaceuticals, Inc.

Limmatech Biologics Ag

Eidgenossische Technische Hochschule Zurich

Glycovaxyn Ag

Manuela Mally

Michael T Kowarik

Stefan Jochen Kemmler

Michael L Wetter

Darren Robert Abbanat

Micha Andres Häuptle

Patricia Ibarra Yon

Veronica Gambillara Fonck

Veronica Gambillara

Jeroen Geurtsen

Eveline Marleen Weerdenburg

Pieter Jan Burghout

Martin Edward Braun

Jan Theunis Poolman

Maria Paula Carranza Sandmeier

Jan Poolman

Peter Wilhelmus Maria Hermans

Bert Jacquemyn

Kellen Cristhina Fae

Amirreza Faridmoayer

Markus Aebi

Ivan Hang

Timothy Keys

Christian A Lizak

Micha A Häuptle

Rainer Follador

Chia-wei Lin

Michael Thomas Kowarik

Fonck Veronica Gambillara

Micha A Hauptle

Michael Lukas Wetter

Micha Andres Hauptle

Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic. (ExPEC).

Methods of producing bioconjugates ofO-antigen polysaccharides, compositions thereof, and methods of use thereof

Provided herein is anO polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.

Polysaccharide and uses thereof

Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic(ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates ofpolysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of(EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Methods and compositions for immune protection against extra-intestinal pathogenic

A bioconjugate of anglucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying theO4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of anglucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additionalO-antigen polysaccharides to induce antibodies against anglucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic(ExPEC).

Bioconjugates ofO-antigen polysaccharides, methods of production thereof, and methods of use thereof

Described herein are compositions and methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.

Engineered and fully-functional customized glycoproteins

Methods of producing bioconjugates ofo-antigen polysaccharides, compositions thereof, and methods of use thereof

[object Object]

Described herein are methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.

Methods of producing glycosylated proteins

Provided herein is a novelO polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.

Provided herein is a novelO polysaccharide, O25B. Also provided herein are prokaryotic host cells comprising enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates comprise O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, comprising O25B and/or bioconjugates comprising O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further comprise one or more additional bioconjugates.

Growing community of inventors

Watt, Switzerland

Manuela Mally